Could a new drug halt hair loss from frontal fibrosing alopecia?
NCT ID NCT06240351
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This pilot study tests the safety and effectiveness of baricitinib, a drug that targets inflammation, in 15 women with active frontal fibrosing alopecia (FFA). FFA is a condition that causes scarring and permanent hair loss, mainly at the front of the scalp and eyebrows. The study measures changes in disease activity using a special scoring system and looks for improvements in symptoms like itching and redness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRONTAL FIBROSING ALOPECIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.